Structure and Molecular Mechanism of Action
The botulinum toxin A molecule consists of two chains connected by a disulfide bond: a heavy chain (molecular weight ~100 kDa) and a light chain (~50 kDa). Synaptic transmission blockade occurs in several stages:
- Binding. The heavy chain interacts with specific receptors on the presynaptic membrane of nerve terminals.
- Internalization. The toxin enters the neuron via endocytosis.
- Proteolysis. Inside the cell, the light chain exhibits enzymatic activity (acts as a protease). Its targets are the proteins of the SNARE complex, which are responsible for fusing synaptic vesicles with the cell membrane. The toxin cleaves presynaptic membrane proteins (SNAP-25 and syntaxin) and the vesicle membrane protein (synaptobrevin).
- Blockade. Due to the inability of vesicles to fuse with the membrane, the release of acetylcholine into the synaptic cleft becomes impossible.
Pharmacological Effects
The drug acts exclusively at the level of the peripheral nervous system (the molecule does not cross the blood-brain barrier).
- Skeletal muscle. Reduced neurotransmitter release causes peripheral paralysis (myorelaxation). Crucially, the release of trophic factors from vesicles is not impaired, meaning injections do not lead to complete muscle atrophy.
- Autonomic nervous system. Impulse transmission in cholinergic synapses is disrupted. Clinically, the most significant effect is the blockade of sympathetic cholinergic fibers innervating sweat glands, leading to marked anhidrosis.
Production and Standardization
Pharmaceutical preparations (e.g., Botox, Dysport) are derived from Clostridium botulinum cultures through fermentation, purification, and crystallization. They are supplied as a lyophilized powder for injection.
The preparation contains the neurotoxin and hemagglutinin. The latter protects the toxin from degradation and limits its diffusion into adjacent tissues, localizing the effect.
Because the composition of biological products varies, chemical analysis is insufficient, so biological standardization is used. Activity is measured in mouse units (U). One U is the quantity of toxin that causes the death of 50% of mice (LD50) of a specific strain and weight within three days following intraperitoneal administration.
Clinical Application
Unlike toxic doses that cause respiratory muscle paralysis and death, therapeutic doses are extremely small and do not affect overall motor activity. The toxin remains concentrated at the injection site, after which negligible amounts enter systemic circulation and are rapidly metabolized.
1. Spastic conditions (intramuscular or subcutaneous)
- Indications: blepharospasm, strabismus, spasticity following strokes or CNS trauma, multiple sclerosis, cerebral palsy, dystonic syndromes (cervical dystonia, hemifacial spasm).
- Features: the effect lasts 4–6 months. Function recovers only after reinnervation (sprouting)—the outgrowth of new collateral nerve terminals.
2. Hyperhidrosis and cosmetology (intradermal)
- Indications: excessive sweating of the axillae, palms, soles (blockade of eccrine/apocrine glands), as well as correction of facial expression lines.
- Features: duration of effect is 6–8 months.
Complications and Contraindications
Botulinum toxin therapy may be accompanied by adverse reactions:
- Local: pain and microhematomas at the injection site.
- Systemic: mild general fatigue (lasting up to 1 week, more common with higher doses).
- Specific: dependent on the injection site (ptosis, tearing, dysphagia).
- Immunogenicity: formation of antibodies against the hemagglutinin complex is possible, which can reduce therapy efficacy.
Absolute contraindications: myasthenia gravis (due to the risk of worsening weakness), pregnancy, and breastfeeding.